Vudalimab

also known as XmAb20717 · XmAb2071

Developed for: castration-resistant prostate carcinoma · cervical carcinoma · non-small cell lung carcinoma · small cell lung carcinoma · anal squamous cell carcinoma · basal cell carcinoma · biliary tract cancer · breast carcinoma
+30 more
· cervical cancer · cholangiocarcinoma · colon carcinoma · endometrial cancer · endometrial carcinoma · fallopian tube carcinoma · head and neck squamous cell carcinoma · hepatocellular carcinoma · high grade malignant neoplasm · Hodgkins lymphoma · melanoma · mesothelioma · nasopharyngeal carcinoma · ovarian cancer · ovarian carcinoma · peritoneal mesothelioma · pleural mesothelioma · prostate adenocarcinoma · prostate carcinoma · rectal cancer · renal cell carcinoma · salivary gland carcinoma · squamous cell carcinoma of penis · thymic carcinoma · thymoma · thyroid gland undifferentiated (anaplastic) carcinoma · thyroid Hurthle cell carcinoma · urothelial carcinoma · uterine adnexa cancer · vulvar carcinoma
Investigated by: Xencor, Inc. · ICON plc · M.D. Anderson Cancer Center · National Cancer Institute (NCI) · Abramson Cancer Center at Penn Medicine · Bayer
+2 more
· Emory University · Northwestern University

201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT05733351	Aug 2023 → Jun 2025	prostate adenocarcinoma	Emory University	Terminated	No outcome recorded
Phase 1	NCT03517488	Jul 2018 → Jun 2022	anal squamous cell carcinoma, basal cell carcinoma, breast carcinoma, cervical cancer +20	Xencor, Inc.	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT06173505	Dec 2023 → Dec 2025	non-small cell lung carcinoma	Xencor, Inc.	Terminated	No outcome recorded
Phase 26 trials
Phase 2	NCT05900648	May 2023 → Feb 2024	colon carcinoma, rectal cancer	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 2	NCT05337735	Aug 2022 → Dec 2026	Hodgkins lymphoma, cervical carcinoma, high grade malignant neoplasm, peritoneal mesothelioma +2	M.D. Anderson Cancer Center	Suspended	No outcome recorded
Phase 2	NCT05032040	Jul 2022 → Oct 2025 overdue	castration-resistant prostate carcinoma, cervical carcinoma, endometrial cancer, ovarian cancer	Xencor, Inc.	Active not recruiting	No outcome recorded
Phase 2	NCT05453799	Jul 2022 → Jul 2026 overdue	thyroid Hurthle cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma	Northwestern University	Active not recruiting	No outcome recorded
Phase 2	NCT05297903	Apr 2022 → Dec 2026 expected	biliary tract cancer	Abramson Cancer Center at Penn Medicine	Active not recruiting	No outcome recorded
Phase 2	NCT05005728	Oct 2021 → Jun 2025	castration-resistant prostate carcinoma	Xencor, Inc.	Completed	No outcome recorded

Every value below carries the sentence it was read from. 9 sources stand behind the page.

Field	Value	Cited text
Known as	vudalimab	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05032040 ↗ 4 NCT05005728 ↗ NCT06173505 ↗ NCT05453799 ↗ NCT05733351 ↗
Known as	XmAb2071	“To evaluate the antineoplastic efficacy of vudalimab (XmAb2071) in anaplastic thyroid cancer, as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.” NCT05453799 ↗
Known as	XmAb20717	“A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies” NCT05032040 ↗ 5 “XmAb®20717 (Vudalimab)” NCT05005728 ↗ NCT05297903 ↗ NCT05900648 ↗ NCT03517488 ↗ NCT05337735 ↗
Action	Inhibit	“vudalimab, an anti-PD-1/CTLA-4 bispecific antibody” NCT06173505 ↗
Modality	Monoclonal antibody	“Monoclonal bispecific antibody” NCT03517488 ↗
Route	Intravenous	“administered by intravenous dosing” NCT03517488 ↗